Investment Rating - The investment rating for the company is "Accumulate" [6][19]. Core Insights - The company, Longjing Environmental Protection, has shown steady growth in 2025, with its core environmental business maintaining high order levels. The green electricity segment has begun to contribute significantly to profits, while energy storage cells have achieved profitability, and mining trucks have made product breakthroughs. The new energy sector is entering a phase of accelerated profit realization [2][12]. Financial Summary - Total revenue for 2025 is projected at 11,872 million yuan, representing an 18.5% increase from 2024. The net profit attributable to shareholders is expected to reach 1,112 million yuan, a 33.9% increase year-on-year. The earnings per share (EPS) for 2025 is estimated at 0.88 yuan [5][12]. - The company’s comprehensive gross margin for 2025 is 25.17%, reflecting a year-on-year improvement of approximately 0.33 percentage points, indicating a steady enhancement in profitability [12]. - The company’s cash flow from operating activities is projected at 16.18 billion yuan, despite a 26% year-on-year decline, maintaining a good level [12]. Business Segments - The environmental protection business has a robust order backlog, with new contracts for environmental equipment engineering amounting to 10,258 million yuan in 2025. The order reserve for environmental equipment engineering contracts stands at 18,890 million yuan [12]. - In the new energy sector, green electricity projects have started to yield significant profits, with operational capacity reaching approximately 1.2 GW. The energy storage cell business has also become profitable, with around 8 GWh delivered in 2025 [12]. Valuation and Target Price - The target price for the company has been raised to 24.00 yuan, based on a 20x price-to-earnings (PE) ratio for 2026, reflecting the accelerated profit realization in the new energy business [12][14].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 28.47 CNY based on a target PE of 20x for 2026, corresponding to a market value of 630 billion CNY [3][6]. Core Insights - The newly launched game "Last Asylum: Plague" has shown promising initial performance, particularly in the overseas markets, with significant revenue growth following its release on February 12, 2026, and subsequent Android launch in March [1][2]. - The game differentiates itself through its unique medieval theme centered around the "Black Death" and the role of a physician, which contrasts with more common zombie or war themes. This narrative approach emphasizes keywords like "hospital," "treatment," and "survival," creating a compelling user experience [2]. - The report forecasts the company to achieve revenues of 16.6 billion CNY in 2025, 18.9 billion CNY in 2026, and 21.1 billion CNY in 2027, with corresponding net profits of 3.04 billion CNY, 3.15 billion CNY, and 3.56 billion CNY respectively [3][5]. Financial Projections - Revenue and profit forecasts indicate a year-over-year growth of -5%, +14%, and +12% for 2025, 2026, and 2027 respectively, with net profit growth rates of +14%, +4%, and +13% for the same years [3][5]. - The company is expected to maintain a stable operating profit margin, with a projected operating profit of 3.66 billion CNY in 2026 [3][5]. - The report highlights a significant increase in downloads and revenue rankings for "Last Asylum: Plague," with the game entering the top 50 free and best-selling iOS games in multiple regions shortly after launch [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve revenue of 6.7 billion yuan in 2025, representing a year-on-year increase of 8.83%. The net profit attributable to shareholders is projected to be 1.739 billion yuan, up 11.66% [4] - The company maintains a strong focus on the health supplement sector, particularly in the ejiao category, and is optimistic about the long-term growth potential from its product diversification and industry chain layout [4] - The company plans to distribute a cash dividend of 14.31 yuan per 10 shares, totaling 922 million yuan, which reflects a commitment to high shareholder returns [6] Financial Performance Summary - In 2025, the company's revenue from ejiao and related products reached 6.198 billion yuan, an increase of 11.80%, with a gross margin of 74.84% [5] - The company’s operating profit for 2025 is projected at 2.071 billion yuan, with a net profit margin of 25.95% [4][8] - The earnings per share (EPS) for 2025 is estimated at 2.70 yuan, with future projections of 3.04 yuan for 2026 and 3.45 yuan for 2027 [8] Valuation Metrics - The current price-to-earnings (P/E) ratio is projected to be 18.5 for 2026, 16.2 for 2027, and 14.3 for 2028, indicating a favorable valuation trend [4][8] - The company has maintained a high dividend payout ratio, averaging around 70% over the years, which enhances shareholder confidence [6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 721.65 CNY based on a 51x PE valuation for comparable companies in 2026 [3][10][6]. Core Insights - The company is expected to benefit from advancements in storage technology, which will significantly increase the demand for etching and thin film deposition equipment. The share of these technologies in capital expenditures for storage production lines is projected to rise substantially due to the trend towards 3D stacking technology [9][3]. - The company has established a comprehensive product lineup in the thin film deposition equipment sector, achieving significant breakthroughs in high-end products. The revenue from thin film deposition equipment is expected to exceed 6.5 billion CNY in the first half of 2025 [9]. - In the etching equipment sector, the company has a well-rounded product offering, with its CCP equipment dominating applications in 8-inch production lines and successfully applied in 12-inch production lines as well. Revenue from etching equipment is anticipated to surpass 5 billion CNY in the first half of 2025 [9]. Financial Forecasts - The company's projected net profits for 2025, 2026, and 2027 are 7.04 billion CNY, 10.26 billion CNY, and 13.05 billion CNY respectively, with corresponding year-on-year growth rates of 25.3%, 45.7%, and 27.2% [5][10]. - Revenue forecasts indicate a growth trajectory from 22.08 billion CNY in 2023 to 62.54 billion CNY by 2027, reflecting a compound annual growth rate of approximately 30.3% [5][10]. - The gross margin is expected to stabilize around 43% by 2027, with net profit margins projected to reach 20.9% [5][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's performance in 2025 met market expectations, with total revenue of 7.295 billion yuan, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 659.54 million yuan, up 14.8% year-on-year [7] - The AIDC (Automatic Identification and Data Capture) business has become a strong growth engine, achieving revenue of 1.34 billion yuan in 2025, a significant increase of 197% year-on-year [7] - The company is expanding its overseas revenue and orders, with total orders on hand reaching 7.21 billion yuan, an increase of 11% year-on-year, and foreign sales revenue of 2.3 billion yuan, up 16% year-on-year [7] - The company has launched new products in the SST (Superconducting Superconducting Transformer) category, achieving a technical lead with an efficiency of over 98% [7] - Operating cash flow has significantly improved, with a net inflow of 601 million yuan in 2025, a year-on-year increase of 1725% [7] Financial Summary - Total revenue forecast for 2024 is 6.901 billion yuan, with a projected growth rate of 3.5% [1] - The net profit attributable to shareholders is expected to reach 659.54 million yuan in 2025, with a growth rate of 14.82% [1] - The company's P/E ratio is projected to decrease from 64.35 in 2024 to 23.41 in 2028, indicating improving valuation [1] - The gross profit margin for 2025 is 25.9%, an increase of 1.5 percentage points year-on-year [7] - The company's total assets are projected to grow from 12.391 billion yuan in 2025 to 20.945 billion yuan by 2028 [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 met market expectations, with total revenue of 7.295 billion yuan, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 659.54 million yuan, up 14.8% year-on-year [7] - The AIDC (Automatic Identification and Data Capture) business has become a strong growth engine, achieving revenue of 1.34 billion yuan in 2025, a significant increase of 197% year-on-year [7] - The company is expanding its overseas revenue and orders, with total orders on hand reaching 7.21 billion yuan, an increase of 11% year-on-year, and foreign sales revenue of 2.3 billion yuan, up 16% year-on-year [7] - The company has made advancements in new product development, particularly in SST (Superconducting Superconducting Transformer) products, which have achieved technical leadership [7] - Operating cash flow has significantly improved, with net cash inflow from operating activities reaching 601 million yuan, a year-on-year increase of 1725% [7] Financial Summary - Total revenue forecast for 2024 is 6.901 billion yuan, with a projected growth rate of 3.5% [1] - The net profit attributable to shareholders is expected to reach 659.54 million yuan in 2025, with a growth rate of 14.82% [1] - The company's gross margin for 2025 is projected at 25.9%, an increase of 1.5 percentage points year-on-year [7] - The P/E ratio for the current price is estimated to be 64.35 for 2024, decreasing to 23.41 by 2028 [1]

Investment Rating - The report maintains an "Accumulate" rating for China Jushi (600176) [1] Core Views - China Jushi achieved significant growth in 2025, with operating revenue of 18.88 billion yuan, a year-on-year increase of 19.08%, and a net profit attributable to shareholders of 3.285 billion yuan, up 34.38% year-on-year. The non-recurring net profit reached 3.48 billion yuan, marking a substantial increase of 95% year-on-year [2][4] - The gross profit margin showed a continuous recovery, reaching 33.12% in 2025, an increase of 8.1 percentage points compared to 2024. The quarterly gross profit margins were 30.53%, 33.84%, 32.82%, and 35.06% respectively, indicating a steady improvement [2][4] - The company reported a significant increase in sales and gross profit margin in its fiberglass segment, with sales volume of 3.2026 million tons and revenue of 18.345 billion yuan, representing an 18.51% increase year-on-year. The gross profit margin for this segment increased by 7.87 percentage points to 32.21% [2][4] Summary by Relevant Sections Financial Performance - In 2025, the company’s operating revenue was 18.88 billion yuan, with a net profit of 3.415 billion yuan. The operating profit was 4.376 billion yuan, and the total profit was 4.15 billion yuan [4] - The company’s ROE (TTM) was 10.57%, and the operating cash flow improved significantly from 2 billion yuan in 2024 to 4.2 billion yuan in 2025 [2][4] Future Projections - The forecast for EPS from 2026 to 2028 is 1.29 yuan, 1.49 yuan, and 1.66 yuan respectively, with corresponding PE ratios of 17.6 times, 15.2 times, and 13.7 times [2][4]

Investment Rating - The investment rating for the company is "Accumulate" [1] Core Insights - The company achieved a revenue of 51.459 billion yuan in 2025, representing a year-on-year increase of 59.17%, and a net profit of 1.345 billion yuan, up 358.09% year-on-year [2] - The total number of stores exceeded 18,000, with a net increase of 4,118 stores compared to the end of 2024, indicating significant expansion and operational efficiency [2] - The average revenue per store in 2025 was 3.13 million yuan, showing a decline of 6.9% year-on-year, but the profitability is gradually recovering [2] - The company plans to distribute a cash dividend of 8.50 yuan per 10 shares to all shareholders [2] Summary by Sections Financial Performance - The company’s gross profit margin improved to 12.4% in 2025, with a net profit margin of 4.98%, an increase of 2.28 percentage points year-on-year [4] - The net profit for the company's volume business reached 2.533 billion yuan in 2025, a year-on-year increase of 195% [4] - The company forecasts revenue for 2026 to be 64.481 billion yuan, with an EPS of 10.89 yuan, reflecting a strong growth trajectory [7] Business Expansion - The company’s store count reached 18,314, covering all 30 provinces, autonomous regions, and municipalities in China, with a focus on expanding in key regions [2] - The company is enhancing its competitive advantage by deepening its volume business and expanding its product matrix to include non-snack essentials [5] - The company is also pursuing an H-share listing to enhance its international strategy and plans a mid-term dividend payout of up to 50% [6] Market Position - The company has become the first snack chain brand in the industry to exceed 10,000 stores, leading in GMV [4] - The company is leveraging its supply chain efficiency and digital systems to improve profitability and reduce costs [4] - The registered member count is nearing 190 million, with over 140 million active transaction members, indicating strong customer loyalty [2]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 28.47 CNY based on a projected PE of 20x for 2026, corresponding to a target market capitalization of 630 billion CNY [3][6]. Core Insights - The newly launched game "Last Asylum: Plague" has shown strong initial performance, particularly in the European and American markets, indicating a promising revenue and profit contribution in the future [1][2]. - The game differentiates itself with a unique theme centered around the medieval "Black Death" and the role of a physician, which contrasts with more common zombie or war themes. This narrative approach has successfully engaged players and established a solid initial experience [2]. - The company anticipates revenue growth from 2025 to 2027, projecting revenues of 166 billion CNY, 189 billion CNY, and 211 billion CNY, with corresponding net profits of 30.4 billion CNY, 31.5 billion CNY, and 35.6 billion CNY [3]. Financial Projections - Revenue and profit forecasts indicate a slight decline in 2025, followed by a recovery in subsequent years, with year-over-year growth rates of -5%, +14%, and +12% for revenue, and +14%, +4%, and +13% for net profit from 2025 to 2027 [3][5]. - The company is expected to achieve an operating profit margin that turns positive as the new game continues to gain traction, leading to increased revenue and profit contributions [2][3]. Market Performance - The game "Last Asylum: Plague" has entered the top 50 free and best-selling iOS game charts in multiple regions, reflecting its successful market penetration since its global launch [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to face operational pressure in 2025, but there is optimism regarding its growth potential in the silver health sector, leading to the maintenance of the "Buy" rating [4] - In 2025, the company achieved revenue of 6.575 billion yuan, a year-on-year decrease of 21.74%, and a net profit attributable to the parent company of 350 million yuan, down 46.00% [4] - The company is adjusting its profit forecasts for 2026-2028, expecting net profits of 244 million yuan, 358 million yuan, and 449 million yuan respectively, with corresponding EPS of 0.32, 0.47, and 0.59 yuan [4] Financial Performance Summary - In 2025, the company's gross margin was 38.52%, down 4.94 percentage points, and the net margin was 6.37%, down 2.57 percentage points [4] - The sales expense ratio for 2025 was 25.98%, down 0.51 percentage points, while the management expense ratio increased to 5.76%, up 1.34 percentage points [4] - The company’s oral dosage revenue was 2.313 billion yuan, down 37.36%, while injection revenue was 607 million yuan, up 12.57% [5] - The overall revenue from drug and device wholesale and retail was 3.270 billion yuan, down 10.52% [5] R&D and Market Focus - The company is focusing on the aging health and chronic disease management sectors, with ongoing clinical trials for several innovative drugs [6] - The company is advancing a Class 1 new drug for ischemic stroke and a Class 1 new drug for non-alcoholic fatty liver disease, both in clinical trials [6] Financial Projections - The company’s projected revenues for 2026, 2027, and 2028 are 6.791 billion yuan, 7.256 billion yuan, and 7.726 billion yuan respectively, with year-on-year growth rates of 3.3%, 6.8%, and 6.5% [8] - The projected gross margins for the next three years are 40.9%, 41.3%, and 41.6% [8] - The projected P/E ratios for 2026, 2027, and 2028 are 36.4, 24.8, and 19.7 respectively [8]